Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism.
暂无分享,去创建一个
H. Braak | M. Tsolaki | R. Nitsch | C. Hock | J. Streffer | A. Papassotiropoulos | G. Binetti | L. Benussi | D. Thal | A. Brühl | D. Lütjohann | E. Ghebremedhin | T. Pasch | A. Maddalena | T. Hegi | F. Nicosia | S. Schmid | Vassiliki Iakovidou | Muriel Träxler
[1] J. Trojanowski,et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease , 2004, Acta Neuropathologica.
[2] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[3] P. S. St George-Hyslop,et al. The gene encoding nicastrin, a major gamma-secretase component, modifies risk for familial early-onset Alzheimer disease in a Dutch population-based sample. , 2002, American journal of human genetics.
[4] S. DeKosky,et al. Distribution of plasma α1-antichymotrypsin levels in Alzheimer disease patients and controls and their genetic controls , 2002, Neurobiology of Aging.
[5] F. Jessen,et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. , 2002, Journal of psychiatric research.
[6] B. Winblad,et al. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells , 2001, Neuroscience Letters.
[7] P. Sullivan,et al. Genetic case-control association studies in neuropsychiatry. , 2001, Archives of general psychiatry.
[8] R. Nitsch,et al. Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.
[9] J. Hardy,et al. Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.
[10] E. Kojro,et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Bergmann,et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] M. Michikawa,et al. Site-specific Phosphorylation of Tau Accompanied by Activation of Mitogen-activated Protein Kinase (MAPK) in Brains of Niemann-Pick Type C Mice* , 2001, The Journal of Biological Chemistry.
[13] H Jick,et al. Statins and the risk of dementia , 2000, The Lancet.
[14] G. Celesia,et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.
[15] H. Braak,et al. Sequence of Aβ‐Protein Deposition in the Human Medial Temporal Lobe , 2000 .
[16] F. Jessen,et al. Plasma 24S‐hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease , 2000, Neuroreport.
[17] K. Blennow,et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.
[18] J M Guileyardo,et al. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Wahren,et al. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. , 1998, Journal of lipid research.
[20] B. Strooper,et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] D. Lütjohann,et al. Importance of a Novel Oxidative Mechanism for Elimination of Brain Cholesterol , 1997, The Journal of Biological Chemistry.
[22] D. Lütjohann,et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[23] W. Klein,et al. Cholesterol Modulates -Secretase Cleavage of Amyloid Precursor Protein (*) , 1996, The Journal of Biological Chemistry.
[24] M. Ilyas Kamboh,et al. A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism , 1995, Nature Genetics.
[25] U. Diczfalusy,et al. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. , 1995, Analytical biochemistry.
[26] J. Morris,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.
[27] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[28] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[29] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.